Rezaei Zadeh Rukerd Mohammad, Shahrbabaki Fatemeh Rafiei, Movahedi Mitra, Honarmand Amin, Pourzand Pouria, Mirafzal Amirhossein
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
Department of Emergency Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Int J Emerg Med. 2024 Apr 2;17(1):49. doi: 10.1186/s12245-024-00621-5.
Ondansetron is one of the most commonly used drugs in the emergency department (ED) for treating nausea and vomiting, particularly in intravenous (IV) form. Nevertheless, it has been shown to prolong QT interval and increase the risk of ventricular dysrhythmias. This study evaluated the associations between single IV ondansetron dosage and subsequent QTc prolongation in the ED.
In this prospective observational study, a total number of 106 patients presenting to the ED in a 3-month period with nausea and vomiting treated with IV ondansetron were enrolled. QT and QTc intervals were measured at baseline (QT0 and QTc0), and 60 min (QT60 and QTc60) following a single-dose administration of ondansetron at 4 or 8 mg doses. To evaluate the predictive ability of these variables, we employed receiver operating characteristic (ROC) curve analyses.
The predictive models for QTc prolongation 1-hour post-ondansetron administration showed the following: at baseline, the area under curve of 0.70 for QT, 0.71 for QTc, and 0.64 for dosage. Conversely, a QTc0 = 375 msec indicated a QTc60 > 480 msec with a specificity of 97%. Additionally, a QTc0 of 400 msec had a sensitivity of 100% in predicting a QTc60 < 480 msec, while a QTc0 > 460 msec predicted a QTc60 > 480 msec with a specificity of 98%. Moreover, 8 mg doses were associated with higher rates of QTc60 prolongation, while 4 mg doses favored maintaining QTc60 within normal limits.
Our study demonstrates the predictive capacity of QT0, QTc0, and ondansetron dosage in forecasting QTc60 prolongation (> 480 msec) post-ondansetron administration. These findings advocate for their incorporation into clinical protocols to enhance safety monitoring in adult ED patients.
昂丹司琼是急诊科最常用的治疗恶心和呕吐的药物之一,尤其是静脉注射剂型。然而,它已被证明会延长QT间期并增加室性心律失常的风险。本研究评估了急诊科单次静脉注射昂丹司琼剂量与随后QTc延长之间的关联。
在这项前瞻性观察性研究中,纳入了在3个月内到急诊科就诊、接受静脉注射昂丹司琼治疗恶心和呕吐的106例患者。在基线时(QT0和QTc0)以及单次给予4或8毫克剂量昂丹司琼后60分钟(QT60和QTc60)测量QT和QTc间期。为了评估这些变量的预测能力,我们采用了受试者操作特征(ROC)曲线分析。
昂丹司琼给药后1小时QTc延长的预测模型显示如下:在基线时,QT的曲线下面积为0.70,QTc为0.71,剂量为0.64。相反,QTc0 = 375毫秒表明QTc60 > 480毫秒,特异性为97%。此外,QTc0为400毫秒在预测QTc60 < 480毫秒时敏感性为100%,而QTc0 > 460毫秒预测QTc60 > 480毫秒时特异性为98%。此外,8毫克剂量与更高的QTc60延长率相关,而4毫克剂量有利于将QTc60维持在正常范围内。
我们的研究证明了QT0、QTc0和昂丹司琼剂量在预测昂丹司琼给药后QTc60延长(> 480毫秒)方面的预测能力。这些发现主张将它们纳入临床方案,以加强对成年急诊科患者的安全监测。